ANVISA
- Status: likely_approved
Lymphostat B (BELIMUMAB) regulatory status in Brazil.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. ANVISA has authorised it.
Human Genome Sciences Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.